Showing results (691-700 of 6,300) with videos related to
Sort By:
Pageof 630
Diabetes, Obesity & Metabolism|July 8, 2011
Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptideC M Mack, P A Smith, J R Athanacio, et al.Diabetes, Obesity & Metabolism|August 10, 2011
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexiaP B Jensen, P J Larsen, C Karlsen, et al.Diabetes, Obesity & Metabolism|August 10, 2011
Brain glucose sensing and neural regulation of insulin and glucagon secretionB ThorensDiabetes, Obesity & Metabolism|July 20, 2011
Differential response between diabetes and stress-induced hyperglycaemia to algorithmic use of detemir and flexible mealtime aspart among stable postcardiac surgery patients requiring intravenous insulinK Dungan, C Hall, D Schuster, et al.Diabetes, Obesity & Metabolism|July 20, 2011
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetesA J Farmer, J Oke, R Stevens, et al.Diabetes, Obesity & Metabolism|December 8, 2011
Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind studyR Kawamori, N Inagaki, E Araki, et al.Diabetes, Obesity & Metabolism|December 24, 2011
Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugsC Ll Morgan, S Jenkins-Jones, M Evans, et al.Diabetes, Obesity & Metabolism|November 9, 2011
Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetesJ Wainstein, L Katz, S S Engel, et al.Diabetes, Obesity & Metabolism|September 30, 2011
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO studyI Lazich, P Sarafidis, E de Guzman, et al.Diabetes, Obesity & Metabolism|May 28, 2011
Glucagon antagonism as a potential therapeutic target in type 2 diabetesJ I Bagger, F K Knop, J J Holst, et al.Pageof 630